2. Signaling Pathways
  3. Immunology/Inflammation
  4. Interleukin Related

Interleukin Related

IL

Interleukin Related

Related Products

PDF 1.53 MB

Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.

Interleukin Related Isoform Specific Products:

Interleukin Related Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-183569
    CSF1R-IN-27
    		Inhibitor
    CSF1R-IN-27 is a CSF1R inhibitor with oral effectiveness, kinome-wide selective profile, low cellular cytotoxicity, and CSF1R IC50 values of 19 nM, 88 nM, 173 nM, 797 nM, 1448 nM, and >3000 nM. CSF1R-IN-27 suppresses M-CSF-induced phosphorylation of CSF1R, AKT, and ERK in macrophages, and inhibits hepatic p-CSF1R/p-AKT/p-ERK signaling. CSF1R-IN-27 reduces serum transaminase levels, improves hepatic histopathology, alleviates inflammatory cell infiltration, and decreases circulating TNF-α and IL-6 levels. CSF1R-IN-27 can be used for the research of acute liver injury.
    CSF1R-IN-27
  • HY-173317
    STING-IN-13
    		Inhibitor
    STING-IN-13 is a selective STING inhibitor. STING-IN-13 can effectively inhibit downstream signaling of the STING pathway and inhibit STING-mediated inflammation. STING-IN-13 has low toxicity and can be used to study STING-related inflammatory and autoimmune diseases.
    STING-IN-13
  • HY-132831C
    Selnoflast monopotassium
    		Inhibitor
    Selnoflast (RO7486967) monopotassium, formerly somalix/RG6418/IZD334 monopotassium, is an orally active, potent, selective and reversible small molecule NLRP3 inflammasome inhibitor. Selnoflast monopotassium is a potent inhibitor of IL-1β release stimulated by NLRP3 activation in human Alzheimer's disease (AD) monocyte-derived macrophages. Selnoflast monopotassium is promising for research of AD and systemic inflammatory diseases, such as ulcerative colitis and chronic obstructive pulmonary disease.
    Selnoflast monopotassium
  • HY-N12571A
    (E/Z)-3-Hydroxylicochalcone A
    		Inhibitor
    (E/Z)-3-Hydroxylicochalcone A (Compound 1) is a flavonoid found in licorice (Glycyrrhiza inflata and
    Glycyrrhiza uralensis), with antioxidant and anti-inflammatory activity. (E/Z)-3-Hydroxylicochalcone A inhibits lipid peroxidation in rat liver microsomes. (E/Z)-3-Hydroxylicochalcone A inhibits LPS (HY-D1056)-induced ROS, NO, IL-6, and PGE2 production.
    (E/Z)-3-Hydroxylicochalcone A
  • HY-P992162
    23ME-00610
    		Activator
    23ME-00610 is a humanized effector-function-null IgG1 antibody targeting CD200R1, with a Kd of <0.1 nM for hCD200R1. 23ME-00610 blocks the binding of CD200 to CD200R1 and inhibits the recruitment of the downstream adaptor protein DOK2 to CD200R1. 23ME-00610 restores IL-2 production suppressed by CD200. 23ME-00610 induces cytokine production in cells. 23ME-00610 enhances cell-mediated tumor cell killing in vitro. 23ME-00610 can be used for melanoma research.
    23ME-00610
  • HY-P992335
    COM503
    		Inhibitor
    COM503 is a high-affinity anti-IL18BP human monoclonal antibody with a Kd value of 0.291 pM. COM503 binds to IL18BP, blocks the IL18BP:IL18 interaction, displaces IL18 from preformed complexes, and enhances the activation and function of T cells and NK cells. COM503 induces anti-tumor effects by relieving the activity inhibition of endogenous IL18 in the tumor microenvironment. COM503 can be used for cancer research. The recommended isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
    COM503
  • HY-165557
    GSK1370319A
    		Inhibitor
    GSK1370319A is a human P2X7 receptor inhibitor with an IC50 of 474 nM and a Ki of 176 nM. GSK1370319A inhibits the production of IL-1β, reduces the generation of reactive oxygen species (ROS), and increases the survival rate of macrophages. GSK1370319A can be used for the research of inflammatory bowel disease.
    GSK1370319A
  • HY-P992031
    Anti-IL-2R gamma Antibody
    		Inhibitor
    Anti-IL-2R gamma Antibody is an anti-IL-2R gamma antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Anti-IL-2R gamma Antibody
  • HY-167845S
    Exemestane-19-d3
    Exemestane-19-d3 is the deuterium labeled LD03-DEX (HY-167845). LD03-DEX is a precursor compound of dexamethasone (HY-14648) with immunosuppressive activity.
    Exemestane-19-d<sub>3</sub>
  • HY-P991602
    NI-1201
    		Inhibitor
    NI-1201 is a monoclonal antibody that targets, in the human IL-6R sequence, the epitope recognized by 25F10 for mice. NI-1201 inhibits both IL-6 cis- and trans-signaling. NI-1201 targets site IIb of hIL-6R. NI-1201 inhibits gp130 binding to IL-6R.
    NI-1201
  • HY-182510
    NTZ-24
    		Inhibitor
    NTZ-24 is a selective STAT3 pathway inhibitor. NTZ-24 suppresses STAT3 phosphorylation at Tyr705, blocks STAT3-DNA interaction, and downregulates the levels of STAT3 downstream target proteins. NTZ-24 induces cell-cycle arrest and promotes apoptosis in cancer cells. NTZ-24 exerts significant antiproliferative activity against HeLa cells (IC50 = 3.3 μM). NTZ-24 can be used for the research of cervical cancer.
    NTZ-24
  • HY-W012732S2
    Isoquinoline-15N
    Isoquinoline-15N is the 15N-labeled Isoquinoline (HY-W012732). Isoquinoline is an analog of pyridine. Isoquinoline-based alkaloids, such as p-tolyl bisisoquinoline, phthaloyl isoquinoline, and naphthyl isoquinoline, exhibit anticancer activity. Berberine, an isoquinoline alkaloid, exerts anti-inflammatory effects in diabetic mice by downregulating the gene expression ratios of pro-/anti-inflammatory and Th1/Th2 cytokines. Additionally, some isoquinoline-based compounds also possess antidepressant, antibacterial, antimalarial, and anti-HIV activities.
    Isoquinoline-<sup>15</sup>N
  • HY-159060
    Coriolus Versicolor Extract
    		Inhibitor
    Coriolus Versicolor Extract is a biological response modifier (BRM) with anti-cancer and anti-migratory properties. Coriolus Versicolor Extract can also inhibit the expression of tumorigenic factors associated with inflammation and can be used in cancer research.
    Coriolus Versicolor Extract
  • HY-149087
    MR2938
    		Inhibitor
    MR2938 is a potent AChE inhibitor, with an IC50 of 5.04 μM. MR2938 also suppresses NO production obviously (IC50 = 3.29 μM). MR2938 suppresses the neuroinflammation through blocking MAPK/JNK and NF-κB signaling pathways. MR2938 can be used for Alzheimer’s disease (AD) research.
    MR2938
  • HY-180608
    TCR-IN-1
    		Inhibitor
    TCR-IN-1 (Compound A-33) is a TCR inhibitor. TCR-IN-1 blocks cytokine (IL-2, TNFα, IFNγ, IL-17A) release.
    TCR-IN-1
  • HY-P991276
    FM-303
    		Inhibitor
    FM-303 is a monoclonal antibody inhibitor targeting interleukin-23 (IL-23). FM-303 is promising for research of immune system diseases and diseases of digestive system.
    FM-303
  • HY-N17326
    Ilekudinol B
    		Inhibitor
    Ilekudinol B is an inhibitor of ACAT and PTP1B, with an IC50 of 5.3 μM and a Ki of 11.6 μM against human PTP1B. Ilekudinol B inhibits the classical pathway of the complement system, with an IC50 of 51 μM. Ilekudinol B inhibits TNF-α-induced cellular IL-8 secretion, promotes glucose uptake in skeletal muscle myotubes, and acts as an insulin mimetic and insulin sensitizer. Ilekudinol B can be used in research related to type 2 diabetes, obesity, and inflammatory diseases.
    Ilekudinol B
  • HY-173407
    P2Y14R antagonist 4
    		Inhibitor
    P2Y14R antagonist 4 (Compound 25l) is an orally active P2Y14R antagonist (IC50: 5.6 nM) with superior binding affinity to P2Y14R over PPTN. P2Y14R antagonist 4 has anti-inflammatory activity and reduces LPS (HY-D1056)-induced proinflammatory cytokines (IL-1β, IL-6, and TNF-α) release.
    P2Y14R antagonist 4
  • HY-182102
    NLRP3-IN-88
    		Inhibitor
    NLRP3-IN-88 (Compound 1) is an NLRP3 inhibitor. NLRP3-IN-88 inhibits IL-1β. NLRP3-IN-88 can be used in research on intestinal diseases and inflammatory diseases.
    NLRP3-IN-88
  • HY-P2630
    Suc-YVAD-pNA
    Suc-YVAD-pNA is a substrate of ICE. Interleukin-1β-converting enzyme (ICE) is a cysteine protease responsible for the cleavage of pre-interleukin-1β (pre-IL-1β) to the mature cytokine and a member of a family of related proteases (the caspases).
    Suc-YVAD-pNA
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity
Interleukin Related Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.